NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. Th

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, welcomed Moriarty to the leadership team: "We are thrilled to have Peter join Klotho Neurosciences as COO. His extensive experience across the pharmaceutical industry, both in the U.S. and globally, will be instrumental as we move forward. Peter has a remarkable track record, including leadership roles at

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to guide the company's strategic direction, this also signals Dr. Langer's strong belief in the company's mission and potential. Dr. Langer is a world-renowned scientist, entrepreneur, and biotechnology pioneer. His groundbreaking work in drug delivery systems and tissue engineering has earned h

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. Th

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, welcomed Moriarty to the leadership team: "We are thrilled to have Peter join Klotho Neurosciences as COO. His extensive experience across the pharmaceutical industry, both in the U.S. and globally, will be instrumental as we move forward. Peter has a remarkable track record, including leadership roles at

10-Q - Klotho Neurosciences, Inc. (0001907223) (Filer)

NT 10-Q - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

424B3 - Klotho Neurosciences, Inc. (0001907223) (Filer)